New drug combo trial aims to control Tough-to-Treat breast cancer
NCT ID NCT07330544
Summary
This study is testing whether adding one or two new drugs to a standard hormone therapy can help control advanced breast cancer that has stopped responding to previous treatments. It will involve 118 women whose cancer is hormone-receptor positive and HER2-negative. Participants will receive different combinations of the drugs entinostat, anlotinib, and fulvestrant to see which is most effective at shrinking tumors and delaying cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGZhejiang, Hangzhou, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.